Prevention of graft versus host disease following allogeneic bone marrow transplantation.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D003524:Cyclosporins / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control*; D006801:Humans; D007075:Immunoglobulin M / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous / Q000401:mortality
D000911:Antibodies, Monoclonal; D003524:Cyclosporins; D007075:Immunoglobulin M; D003520:Cyclophosphamide